Apotex Ferriprox NDA Will Seek First-Line Claim; Fall Submission Planned
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Apotex’ upcoming NDA for the iron-chelating agent Ferriprox will seek a first-line indication for treatment of iron overload in thalassemia patients.